Texas 2021 - 87th Regular

Texas House Bill HB847

Caption

Relating to warning labels for opioid prescription drugs.

Impact

The bill amends existing regulations in the Health and Safety Code related to the dispensing of controlled substances. Specifically, it requires pharmacists to attach a warning label to any container dispensed for a prescription opioid. This change is expected to raise awareness among patients regarding the risks associated with opioid medications, potentially influencing their understanding and usage patterns. By implementing these warnings, the legislation aims to reduce the risk of addiction and overdose from opioid prescriptions.

Summary

House Bill 847 seeks to enhance safety measures associated with the dispensing of prescription opioids by mandating that all opioid prescriptions carry a warning label. These labels will inform patients about the addictive nature of opioids and the inherent risks of overdose. The bill aims to curb opioid misuse by ensuring that patients are better informed about the dangers of the medication they are receiving, which is critical given the ongoing opioid crisis affecting many communities across Texas.

Contention

While supporters of HB 847 argue that the warning labels are a necessary and proactive step in addressing the opioid crisis, there may be some contention around implementation and execution. Some stakeholders, including pharmaceutical representatives and certain pharmacy groups, might raise concerns over the additional burden on pharmacists, who are already tasked with numerous responsibilities and regulatory compliance requirements. There is also a question of the effectiveness of warning labels in actually changing patient behavior regarding opioid use and whether further measures might be necessary to combat the opioid epidemic.

Companion Bills

No companion bills found.

Previously Filed As

TX HB972

Relating to warning labels for opioid prescription drugs.

TX HB816

Relating to warning labels for opioid prescription drugs.

TX HB814

Relating to an acknowledgment on receipt of an opioid prescription drug.

TX HB815

Relating to distinctive packaging for opioid prescription drugs.

TX SB2173

Relating to a pilot program for the safe disposal of prescription drugs, including controlled substance prescription drugs.

TX HB5230

Relating to health benefit plan coverage of prescription drugs for serious mental illnesses and opioid and substance use disorders.

TX HB2411

Relating to the maintenance, administration, and disposal of opioid antagonists on public and private school campuses and to the permissible uses of money appropriated to a state agency from the opioid abatement account.

TX SB629

Relating to the maintenance, administration, and disposal of opioid antagonists on public and private school campuses and to the permissible uses of money appropriated to a state agency from the opioid abatement account.

TX HB4341

Relating to promoting, prescribing, administering, or dispensing prescription drugs for off-label use.

TX SB426

Relating to patient access to prescription drugs for off-label use for COVID-19 treatment.

Similar Bills

CA SB1286

Pharmacy technicians.

CA AB1589

Pharmacy: pharmacist supervision: technicians.

CA SB339

HIV preexposure prophylaxis and postexposure prophylaxis.

CA SB1365

Pharmacy technicians: supervision.

CA SB476

Pharmacy: Pharmacist Employer Advisory Task Force.

CA SB655

Pharmacy.

NJ S1965

Regulates provision of pharmaceutical services in long-term care facilities.

NJ A5248

Regulates provision of pharmaceutical services in nursing homes.